Journal of Psychopharmacology
November 18, 2016
James Rucker, Luke A. Jelen, Sarah Kalen Flynn et al.
187 citations
Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used...
Therapeutic Advances in Psychopharmacology
October 27, 2016
Ananya Mahapatra, Rishi Gupta
37 citations
Psilocybin is a naturally occurring alkaloid, pharmacologically similar to the classic hallucinogen lysergic acid diethylamide (LSD). Although primarily used as a recreational drug or an entheogen in particular cultural settings, recent population based studies have shown that it does not lead to serious physical or mental health problems or dependent use. In view of recent work demonstrating...
Psychiatria i Psychologia Kliniczna
September 30, 2016
Karolina Dydak, Mariola Śliwińska‐mossoń, Halina Milnerowicz
2 citations
Psylocybina jest substancją psychodysleptyczną pochodzenia naturalnego, występuje w grzybach rodzaju Psilocybe. Psychodysleptyki są środkami psychoaktywnymi, które silnie wpływają na percepcję, nastrój i procesy poznawcze człowieka. Psychodeliczne działanie psylocybiny opiera się na pobudzaniu receptorów serotoninergicznych, co prowadzi do wzrostu stężenia serotoniny w mózgu oraz przyczynia się...
PSYCH up2date
September 8, 2016
Fazit Die vorliegende Studie gibt erste Hinweise auf eine Wirksamkeit von Psilocybin bei chronischen Depressionen. Weitere positive Effekte dieser Substanz konnten bereits in anderen Zusammenhängen nachgewiesen werden. Bei nun nachgewiesener, guter Machbarkeit, motivieren die Autoren zu weiteren kontrollierten Studien mit diesem Wirkstoff.
The Lancet Psychiatry
May 17, 2016
Philip J. Cowen
13 citations
"Alice remained looking thoughtfully at the mushroom for a minute, trying to make out which were the two sides of it; and as it was perfectly round, she found this a very difficult question". To resolve the issue, Alice ate the mushroom; in more recent times, however, experimentation with psilocybin-containing magic mushrooms has been strongly discouraged. In the UK, in 2005, magic mushrooms...
Lancet Psychiatry
May 17, 2016
Robin Carhart-Harris, Mark Bolstridge, James Rucker et al.
1,546 citations
BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy...
European Psychiatry
March 1, 2015
Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann et al.
20 citations
Social cognition is a crucial factor influencing development, progress, and treatment of psychiatric disorders. However, social cognition skills are insufficiently targeted by current treatment approaches. In particular, patients suffering from depression show an increased negative reaction to social exclusion and deficits in empathy. The 5HT-1A/2A receptor agonist psilocybin has previously...
Therapeutic Advances in Psychopharmacology
August 1, 2014
David Baumeister, Georgina Barnes, Giovanni Giaroli et al.
Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding their mind-manifesting effects led to their proscription by the mid-20th century, largely without evidence of harm or toxicity and despite nascent data suggesting therapeutic utility in treating depressive illnesses. This review explores their pharmacodynamic actions and the current limited data on...
Jesús Isaac Castillo-Sánchez
preprint
Abstract The COMP006 Phase 3 trial showed that 39% of patients with treatment-resistant depression (TRD) respond to a single 25 mg dose of psilocybin, while 61% do not — at identical dose, protocol, and pharmacological exposure. No mechanistic explanation for this heterogeneity has been established. Here we propose and validate a two-threshold model in which the psilocybin dose-response...
Çağrı Özkurt
preprint
A recent living systematic review in Nature Mental Health found psilocybin reduced depression symptoms across 12 randomized controlled trials, with pooled effect g = 0.90. The original analysis assessed publication bias using Egger’s test, non-significant — but this test has limited power with few studies and cannot produce a bias-corrected estimate. We re-analysed the same open dataset using...